Cantex Pharmaceuticals Competitors and Similar CompaniesClear all
Cantex Pharmaceuticals's competitors and similar companies include Nektar Therapeutics, Omeros, Exelixis and Nykode Therapeutics.
 Cantex Pharmaceuticals Cantex Pharmaceuticals is a pharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancer. |  Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  Nykode Therapeutics Nykode Therapeutics (formerly known as Vaccibody) is a biopharmaceutical company dedicated to the discovery and development of immunotherapies. | |||
Founding Date | Founding Date 2002 | Founding Date 1990 | Founding Date 1994 | Founding Date 1994 | Founding Date 2007 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Weston, US HQ | Locations San Francisco, US HQ Hyderabad, IN Huntsville, US | Locations Seattle, US HQ | Locations Alameda, US HQ | Locations Oslo, NO HQ |
Employees | Employees 650% increase | Employees 61821% increase | Employees 1968% decrease | Employees 1,14712% decrease | Employees 135 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 233.8 m | Valuation ($) 248.6 m | Valuation ($) 8.2 b | Valuation ($) 144.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $55.2m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $2.3b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $83.7m (FY, 2025) | Cost of goods $1.3m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $2.2b (FY, 2025) | Gross profit ($801k) (FY, 2025) |
Net income | Net income N/A | Net income ($164.1m) (FY, 2025) | Net income ($3.4m) (FY, 2025) | Net income $782.6m (FY, 2025) | Net income ($12.2m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 27.4m | Total funding raised $ 45m | Total funding raised $ 354.8m | Total funding raised N/A | Total funding raised $ 31.5m |
For sources of this data, please see the company profile
View Company Profiles
Nektar Therapeutics
HQ
San Francisco, US
Employees
618↑ 21% increase
Nektar Therapeutics is a stage-clinical biopharmaceutical company.
View companyOmeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View company
Exelixis
HQ
Alameda, US
Employees
1,147↓ 12% decrease
Exelixis is an oncology company that develops cancer treatments.
View companyNykode Therapeutics
HQ
Oslo, NO
Employees
135
Nykode Therapeutics (formerly known as Vaccibody) is a biopharmaceutical company dedicated to the discovery and development of immunotherapies.
View company